trending Market Intelligence /marketintelligence/en/news-insights/trending/JcWKEQr_rw7CLPjcYCDQAQ2 content esgSubNav
In This List

Cellectar Biosciences receives patent protection for cancer drug

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Cellectar Biosciences receives patent protection for cancer drug

Cellectar Biosciences Inc. received a patent covering the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as well as associated cancer stem cells.

The patent protection will last through the end of 2035.